

mITT: migraine attacks with 2-hour data (N=234)

Endpoint	Placebo	11% CBD	6% THC+11% CBD		6% THC	
	(n=58)	(n=57)	(n=58)		(n=61)	
	no. (%)	no. (%)	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO
Primary endpoint						
2h PR	27 (47%)	30 (53%)	0.46	0.016*	42 (69%)**	0.008**
Secondary endpoints						
2h PF	9 (16%)	13 (23%)	0.32	0.017*	17 (28%)	0.084
2h MBSF	20 (34%)	23 (40%)	0.52	0.005**	29 (48%)	0.12

ITT: migraine attacks without 2-hour questionnaire were counted as nonresponders (N=247)

Endpoint	Placebo	11% CBD	6% THC+11% CBD		6% THC	
	(n=64)	(n=60)	(n=61)		(n=62)	
	no. (%)	no. (%)	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO
Primary endpoint						
2h PR	27 (42%)	30 (50%)	0.35	0.009**	42 (68%)**	0.002**
Secondary endpoints						
2h PF	9 (14%)	13 (22%)	0.28	0.012*	17 (27%)	0.055
2h MBSF	20 (31%)	23 (38%)	0.40	0.003**	29 (47%)	0.059

Sensitivity Analysis: excluding migraine attacks without 2-hour data time-stamped 1.5-3 hours (N=202)

Endpoint	Placebo	11% CBD	6% THC+11% CBD		6% THC	
	(n=53)	(n=49)	(n=50)		(n=50)	
	no. (%)	no. (%)	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO	<i>p-value</i> vs PBO
Primary endpoint						
2h PR	24 (45%)	26 (53%)	0.38	0.047*	35 (70%)**	0.009**
Secondary endpoints						
2h PF	8 (15%)	11 (22%)	0.26	0.012*	12 (24%)	0.21
2h MBSF	19 (36%)	21 (43%)	0.43	0.014*	24 (48%)	0.19

ITT, intention-to-treat; mITT, modified intention-to-treat; MBSF, most bothersome symptom freedom; PF, pain freedom; PR, pain relief.